PE20130189A1 - Heterobiaril-ciclohexil-tetraazabenzo[e]azulenos - Google Patents
Heterobiaril-ciclohexil-tetraazabenzo[e]azulenosInfo
- Publication number
- PE20130189A1 PE20130189A1 PE2012002067A PE2012002067A PE20130189A1 PE 20130189 A1 PE20130189 A1 PE 20130189A1 PE 2012002067 A PE2012002067 A PE 2012002067A PE 2012002067 A PE2012002067 A PE 2012002067A PE 20130189 A1 PE20130189 A1 PE 20130189A1
- Authority
- PE
- Peru
- Prior art keywords
- benzo
- alkyl
- substitute
- blue
- tetraaza
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE: R1 ES i) H, ii) ALQUILO C1-6 SIN SUSTITUIR O SUSTITUIDO POR 1 A 5 SUSTITUYENTES SELECCIONADOS DE OH, HALOGENO, CIANO Y ALCOXI C1-6, iii) S(O)2-ALQUILO C1-6, iv) C(O)-ALQUILO C1-6, v) C(O)-ALQUILO C1-6, ENTRE OTROS; R2 ES HALOGENO; R3 ES HETEROBIARILO SIN SUSTITUIR O SUSTITUIDO POR 1-5 SUSTITUYENTES SELECCIONADOS DE OH, HALOGENO, CIANO, ALQUILO C1-6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: CIS-1-(4-BENZO[D]ISOXAZOL-3-IL-CICLOHEXIL)-8-CLORO-4H,6H-2,3,5,10b-TETRAAZA-BENZO[E]AZULENO-5-CARBOXILATO DE TERT-BUTILO; 5,6-DIHIDRO-4H-2,3,5,10b-TETRAAZA-BENZO[e]AZULENO,TRANS-1-(4-BENZO[D]ISOXAZOL-3-IL-CICLOHEXIL)-8-CLORO-5,6-DIHIDRO-4H-2,3,5,10b-TETRAAZA-BENZO[E]AZULENO; ENTRE OTROS. REFERIDO ADEMAS A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE OBTENCION. DICHO COMPUESTO ES ANTAGONISTA DEL RECEPTOR DE LA VASOPRESINA V1A, SIENDO UTIL PARA TRATAMIENTO DE TRASTORNOS DEPRESIVOS, HIPERTENSION, DISMENORREA, ANSIEDAD
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10161043 | 2010-04-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20130189A1 true PE20130189A1 (es) | 2013-02-21 |
Family
ID=43991411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2012002067A PE20130189A1 (es) | 2010-04-26 | 2011-04-21 | Heterobiaril-ciclohexil-tetraazabenzo[e]azulenos |
Country Status (35)
Country | Link |
---|---|
US (1) | US8481528B2 (es) |
EP (1) | EP2571879B1 (es) |
JP (1) | JP5579925B2 (es) |
KR (1) | KR101506778B1 (es) |
CN (1) | CN102858778B (es) |
AR (1) | AR081182A1 (es) |
AU (1) | AU2011246553B2 (es) |
BR (1) | BR112012027392A2 (es) |
CA (1) | CA2794824A1 (es) |
CL (1) | CL2012002954A1 (es) |
CO (1) | CO6612268A2 (es) |
CR (1) | CR20120515A (es) |
CY (1) | CY1117145T1 (es) |
DK (1) | DK2571879T3 (es) |
EA (1) | EA021495B1 (es) |
EC (1) | ECSP12012209A (es) |
ES (1) | ES2553246T3 (es) |
HK (1) | HK1176933A1 (es) |
HR (1) | HRP20160051T1 (es) |
HU (1) | HUE028018T2 (es) |
IL (1) | IL222408A (es) |
MA (1) | MA34173B1 (es) |
MX (1) | MX2012012517A (es) |
MY (1) | MY160977A (es) |
NZ (1) | NZ602663A (es) |
PE (1) | PE20130189A1 (es) |
PL (1) | PL2571879T3 (es) |
PT (1) | PT2571879E (es) |
RS (1) | RS54418B1 (es) |
SG (1) | SG184533A1 (es) |
SI (1) | SI2571879T1 (es) |
TW (1) | TWI419891B (es) |
UA (1) | UA110031C2 (es) |
WO (1) | WO2011134877A1 (es) |
ZA (1) | ZA201207693B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2356123T3 (da) * | 2008-11-13 | 2012-10-15 | Hoffmann La Roche | Spiro-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulener |
CN102216304B (zh) * | 2008-11-18 | 2014-07-09 | 弗·哈夫曼-拉罗切有限公司 | 二氢四氮杂苯并薁的烷基环己基醚 |
RU2507205C2 (ru) | 2008-11-28 | 2014-02-20 | Ф. Хоффманн-Ля Рош Аг | Арилциклогексилэфиры дигидротетраазабензоазуленов для применения в качестве антагонистов рецептора вазопрессина v1a |
US8420633B2 (en) | 2010-03-31 | 2013-04-16 | Hoffmann-La Roche Inc. | Aryl-cyclohexyl-tetraazabenzo[e]azulenes |
US8461151B2 (en) | 2010-04-13 | 2013-06-11 | Hoffmann-La Roche Inc. | Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes |
US8481528B2 (en) | 2010-04-26 | 2013-07-09 | Hoffmann-La Roche Inc. | Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes |
US8513238B2 (en) | 2010-05-10 | 2013-08-20 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes |
CN115246781B (zh) * | 2021-04-28 | 2024-03-29 | 南京正大天晴制药有限公司 | 一种沙芬酰胺的制备方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5516774A (en) * | 1993-07-29 | 1996-05-14 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
US5521173A (en) | 1995-01-17 | 1996-05-28 | American Home Products Corporation | Tricyclic benzazepine vasopressin antagonists |
PT1000062E (pt) * | 1997-07-30 | 2004-12-31 | Wyeth Corp | Agonistas triciclicos de vasopressina |
IL144270A0 (en) | 1999-01-19 | 2002-05-23 | Ortho Mcneil Pharm Inc | Tricyclic benzodiazepines as vasopressin receptor antagonists |
US7022699B2 (en) | 2001-04-12 | 2006-04-04 | Wyeth | Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators |
US7109193B2 (en) * | 2001-04-12 | 2006-09-19 | Wyeth | Tricyclic diazepines tocolytic oxytocin receptor antagonists |
SI1597260T1 (sl) * | 2003-02-19 | 2007-04-30 | Pfizer | Spojine triazola, uporabne pri terapiji |
GB0303852D0 (en) | 2003-02-19 | 2003-03-26 | Pfizer Ltd | Triazole compounds useful in therapy |
GB0400700D0 (en) * | 2004-01-13 | 2004-02-18 | Pfizer Ltd | Compounds useful in therapy |
AP2006003768A0 (en) | 2004-05-25 | 2006-10-31 | Pfizer Prod Inc | TetraazabenzoÄeÜazulene derivatives and analogs tehereof |
KR100840852B1 (ko) | 2004-05-25 | 2008-06-23 | 화이자 프로덕츠 인크. | 테트라아자벤조[e]아줄렌 유도체 및 이의 유사체 |
GB0412874D0 (en) * | 2004-06-09 | 2004-07-14 | Pfizer Ltd | Novel pharmaceuticals |
EP1632494A1 (en) | 2004-08-24 | 2006-03-08 | Ferring B.V. | Vasopressin v1a antagonists |
JP2008510789A (ja) * | 2004-08-25 | 2008-04-10 | ファイザー・インク | トリアゾロベンゾジアゼピン及びバゾプレシンアンタゴニストとしてのそれらの使用 |
WO2006114706A1 (en) | 2005-04-26 | 2006-11-02 | Pfizer Limited | Triazole derivatives as vasopressin antagonists |
CA2608718A1 (en) | 2005-05-18 | 2006-11-23 | Pfizer Limited | 1, 2, 4-triazole derivatives as vasopressin antagonists |
KR101129791B1 (ko) | 2007-01-12 | 2012-03-23 | 에프. 호프만-라 로슈 아게 | 스파이로피페리딘 글리신아마이드 유도체 |
CN102216304B (zh) | 2008-11-18 | 2014-07-09 | 弗·哈夫曼-拉罗切有限公司 | 二氢四氮杂苯并薁的烷基环己基醚 |
US8420633B2 (en) | 2010-03-31 | 2013-04-16 | Hoffmann-La Roche Inc. | Aryl-cyclohexyl-tetraazabenzo[e]azulenes |
US8461151B2 (en) | 2010-04-13 | 2013-06-11 | Hoffmann-La Roche Inc. | Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes |
US8481528B2 (en) | 2010-04-26 | 2013-07-09 | Hoffmann-La Roche Inc. | Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes |
US8513238B2 (en) | 2010-05-10 | 2013-08-20 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes |
-
2011
- 2011-04-19 US US13/089,354 patent/US8481528B2/en active Active
- 2011-04-21 ES ES11715545.7T patent/ES2553246T3/es active Active
- 2011-04-21 UA UAA201213289A patent/UA110031C2/uk unknown
- 2011-04-21 PL PL11715545T patent/PL2571879T3/pl unknown
- 2011-04-21 WO PCT/EP2011/056391 patent/WO2011134877A1/en active Application Filing
- 2011-04-21 EA EA201291109A patent/EA021495B1/ru not_active IP Right Cessation
- 2011-04-21 AU AU2011246553A patent/AU2011246553B2/en not_active Ceased
- 2011-04-21 EP EP11715545.7A patent/EP2571879B1/en not_active Not-in-force
- 2011-04-21 RS RS20150763A patent/RS54418B1/en unknown
- 2011-04-21 DK DK11715545.7T patent/DK2571879T3/en active
- 2011-04-21 SI SI201130662T patent/SI2571879T1/sl unknown
- 2011-04-21 PT PT117155457T patent/PT2571879E/pt unknown
- 2011-04-21 NZ NZ602663A patent/NZ602663A/xx not_active IP Right Cessation
- 2011-04-21 HU HUE11715545A patent/HUE028018T2/en unknown
- 2011-04-21 SG SG2012075149A patent/SG184533A1/en unknown
- 2011-04-21 MA MA35327A patent/MA34173B1/fr unknown
- 2011-04-21 BR BR112012027392A patent/BR112012027392A2/pt not_active IP Right Cessation
- 2011-04-21 CN CN201180021078.6A patent/CN102858778B/zh not_active Expired - Fee Related
- 2011-04-21 CA CA2794824A patent/CA2794824A1/en not_active Abandoned
- 2011-04-21 PE PE2012002067A patent/PE20130189A1/es not_active Application Discontinuation
- 2011-04-21 KR KR1020127030686A patent/KR101506778B1/ko not_active IP Right Cessation
- 2011-04-21 JP JP2013506597A patent/JP5579925B2/ja not_active Expired - Fee Related
- 2011-04-21 MY MYPI2012004626A patent/MY160977A/en unknown
- 2011-04-21 MX MX2012012517A patent/MX2012012517A/es active IP Right Grant
- 2011-04-25 AR ARP110101400A patent/AR081182A1/es unknown
- 2011-04-25 TW TW100114337A patent/TWI419891B/zh not_active IP Right Cessation
-
2012
- 2012-09-28 CO CO12170756A patent/CO6612268A2/es not_active Application Discontinuation
- 2012-10-02 EC ECSP12012209 patent/ECSP12012209A/es unknown
- 2012-10-11 CR CR20120515A patent/CR20120515A/es unknown
- 2012-10-11 IL IL222408A patent/IL222408A/en active IP Right Grant
- 2012-10-12 ZA ZA2012/07693A patent/ZA201207693B/en unknown
- 2012-10-23 CL CL2012002954A patent/CL2012002954A1/es unknown
-
2013
- 2013-04-12 HK HK13104455.5A patent/HK1176933A1/xx not_active IP Right Cessation
-
2016
- 2016-01-15 HR HRP20160051TT patent/HRP20160051T1/hr unknown
- 2016-01-19 CY CY20161100048T patent/CY1117145T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20130189A1 (es) | Heterobiaril-ciclohexil-tetraazabenzo[e]azulenos | |
PE20130190A1 (es) | Heteroaril-ciclohexil-tetraazabenzo[e] azulenos como antagonistas de los receptores de vasopresina v1a | |
CN1281274C (zh) | 6-氟双环[3.1.0]己烷衍生物 | |
PE20090892A1 (es) | MODULADORES DUALES DE LOS RECEPTORES 5-HT2a Y D3 | |
PE20071152A1 (es) | Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3 | |
AR052314A1 (es) | Compuestos de tienopiridinona como agonistas del receptor 5-ht4 | |
PE20080362A1 (es) | Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1 | |
PE20121500A1 (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2 | |
AR078756A1 (es) | Moduladores alostericos positivos (map) | |
PE20060777A1 (es) | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas | |
PE20071254A1 (es) | Derivados de sulfonamidas como agentes moduladores de los receptores de orexina y su preparacion | |
PE20120620A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
PE20120062A1 (es) | Derivados de 1-bencil-2-amino-tetralina como inhibidores del transportador de glicina glyt1 | |
PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
PE20091173A1 (es) | Derivados de heteroarilo como antagonistas de receptor de orexina | |
PE20160691A1 (es) | Nuevos derivados de triazolo[4,5-d]pirimidina | |
PE20110410A1 (es) | Derivado de 7-piperidinoalquil-3,4-dihidroquinolona | |
PE20221322A1 (es) | Procedimiento para preparar (4s)-4-(4-ciano-2-metoxi-fenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6- naftiridin-3-carboxilato de 2-cianoetilo mediante separacion de racematos utilizando esteres diastereomericos de acido tartarico | |
CL2012000516A1 (es) | Compuestos derivados de 3-[4-(4-(fenil/piridin/ pirimidin)- piperazin -1-il)-butil]-2, 3-dihidro-4h-croman-4-ona, moduladores del receptor de dopamina d3; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de un desorden neurologico o psiquiatrico, disfuncion erectil o dependencia a drogas, entre otros. | |
AR070797A1 (es) | Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes | |
PE20091407A1 (es) | Antagonistas de aminoalquilbifenilo n,n-disubstituidos de receptores de prostaglandina d2 | |
PE20061144A1 (es) | DERIVADOS DE PIRROLIDINA Y PIPERIDINA ACETILENO COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO METABOTROPICO (mGluRs) | |
AR077227A1 (es) | Compuesto de acido aril/ heteroaril- sustituido carboxilico, su uso para fabricar un medicamento util el tratamiento de afecciones o trastornos mediados por receptores s1p1, tales como esclerosis multiple y composicion farmaceutica que lo comprende | |
AR074466A1 (es) | Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3. | |
CY1116388T1 (el) | 5-(φαινυλο/πυριδινυλο-αιθινυλο)-2-πυριδινο/2-πυριμιδινο-καρβοξαμιδια ως mglur5 ρυθμιστες |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |